Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Rhea-AI Summary

Karyopharm Therapeutics Inc. will be participating in two major conferences to present their innovative cancer therapies. The senior management team will be at the Leerink Partners Global Biopharma Conference on March 12, 2024, and the Barclays 26th Annual Global Healthcare Conference on March 13, 2024.

NEWTON, Mass., March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m. ET in Miami Beach, FL.

A live webcast of the fireside chat at the Barclays conference can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-barclays-26th-annual-global-healthcare-and-leerink-partners-global-biopharma-conferences-302082067.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm Therapeutics Inc. participate in the Leerink Partners Global Biopharma Conference?

Karyopharm Therapeutics Inc. will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024.

Where will the fireside chat at the Barclays 26th Annual Global Healthcare Conference take place?

The fireside chat at the Barclays 26th Annual Global Healthcare Conference will take place in Miami Beach, FL.

How can one access the live webcast of the fireside chat at the Barclays conference?

The live webcast of the fireside chat at the Barclays conference can be accessed under 'Events & Presentations' in the Investor section of the Company's website.